A study looking at high blood pressure and pazopanib treatment (HYPAZ)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

All cancer types




Phase 2

This study is trying to find out why some people get high blood pressure when taking the drug pazopanib.

Pazopanib is a type of drug called a tyrosine kinase inhibitor (TKI for short). TKIs block tyrosine kinases, which are part of pathways that send messages telling cells to divide and grow. Blocking the effect of these tyrosine kinases may stop cancer cells growing.

A side effect of pazopanib can be a rise in blood pressure. Doctors want to find out more about why this happens to some people and not others. They want to find out if pazopanib affects the lining of veins and arteries (blood vessels) and if it is this that causes blood pressure to rise.

The aim of this study is to find out

  • Why some people get raised blood pressure with pazopanib
  • Whether pazopanib affects the lining of blood vessels
  • The best way to treat raised blood pressure caused by pazopanib

Who can enter

You may be able to enter this trial if you

  • Have cancer that your doctor plans to treat with pazopanib
  • Have cancer that can be measured on CT scan or by blood test for example CA125 Open a glossary item or PSA
  • Have satisfactory blood test results
  • Are well enough to carry out all your normal activities, apart from heavy physical work (performance status 0 or 1)
  • Are willing to use reliable contraception if there is any chance that you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if you

  • Have high blood pressure
  • Are taking medication for high blood pressure
  • Have or have had problems with your heart – your doctor will discuss this with you
  • Have an abnormal heart trace (ECG Open a glossary item)
  • Are taking blood thinning tablets called warfarin
  • Have problems with bleeding
  • Have had a blood clot in your leg (DVT) or lung in the last 6 months
  • Have coughed up blood in the last 8 weeks
  • Have cancer in your brain or spinal cord (CNS Open a glossary item) unless it has been treated successfully in the last 6 months and no longer causing you any problems
  • Have an infection that cannot be controlled with tablets
  • Have had major surgery in the last month, or have a wound that hasn’t healed
  • Are unable to absorb medication
  • Are allergic to pazopanib
  • Have had radiotherapy in the last 2 weeks, unless it is to a single area of your body to control pain
  • Have had other treatments such as immunotherapy Open a glossary item, biological therapy or another experimental drug in the last 2 weeks (or earlier if there is any chance some of the drug could still be in your body)
  • Have had pazopanib (or a similar drug such bevacizumab) in the last 12 weeks
  • Are still having side effects from earlier treatment, unless they are very mild
  • Are pregnant or breastfeeding

Trial design

This trial will recruit 52 people. Everyone on the study will take pazopanib.  You take pazopanib as a tablet once a day for 12 weeks in this trial. If test results show that it is working then you can continue to take it for longer.

The researchers will ask for a sample of your blood to use for research. If you do not want to give extra blood samples for this study, you don’t have to. You can still take part in the trial.

Hospital visits

You see the doctors and have some tests before you start treatment. The tests include

  • A physical examination
  • Heart trace (ECG Open a glossary item)
  • Blood pressure
  • Blood tests
  • Urine test
  • CT scan
  • MRI scans (2 scans in 3 days)

You will be shown how to use a blood pressure machine at home and asked to record your blood pressure at different times during the study.

You visit the doctor at week 2 for an ECG, blood and urine tests. At week 3 you have a blood test. Then at week 4, and every 2 weeks afterwards, you have an ECG, blood and urine tests.

The trial team will do tests to look at blood flow through your veins and arteries during the study. These tests take about 3½ hours. They are painless but you do have to lie still for up to 2¼ hours. In one of the tests you have an injection of dye into an artery in your arm. The research team will explain exactly what you need to do for each test.

After 12 weeks of pazopanib you have an ECG, CT scan, MRI scan, blood pressure, blood tests and urine tests.

If the pazopanib has helped, you can continue to take it. Your cancer doctor will see you regularly for blood pressure and blood tests.

If the pazopanib has not helped, you stop taking it. The trial team will see you 4 weeks later for an ECG, blood pressure, blood and urine tests.

Side effects

The most common side effects of pazopanib are

We have more information about the side effects of pazopanib.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Duncan Jodrell

Supported by

Cambridge University Hospitals NHS Foundation Trust
Experimental Cancer Medicine Centre (ECMC)
GlaxoSmithKline (GSK)
NIHR Clinical Research Network: Cancer
NIHR Comprehensive Cambridge Biomedical Research Centre
University of Cambridge

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle - 7977

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page